Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Augusta University Augusta, Georgia, United States
  • Northwestern University Chicago, Illinois, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Research Medical Center Kansas City, Missouri, United States
View all 158 locations
View Trial Details
Active, Not Recruiting

Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission

NCT05502250

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • BE-Bruxelles-STLUC Brussels, Belgium
  • DK-Aarhus N-AUH Aarhus, Denmark
  • DK-Copenhagen-RIGSHOSPITALET Copenhagen, Denmark
  • DK-Odense-OUH Odense, Denmark
View all 15 locations
View Trial Details
Active, Not Recruiting

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

NCT05306301

Conditions
Chemotherapy, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Ematologia con Unità di Trapianto Avellino, AV, Italy
  • Ematologia Presidio Ospedaliero Tortora Pagani, SA, Italy
  • Ematologia ASST Papa Giovanni XXIII Bergamo, Italy
  • Ematologia AOU S.ORSOLA-MALPIGHI Bologna, Italy
View all 24 locations
View Trial Details
Active, Not Recruiting

Zanubrutinib in Primary Cold Agglutinin Disease

NCT06067048

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations
  • UZ leuven Leuven, Belgium
  • AZ Delta Roeselare, Belgium
  • Rigshospitalet Copenhagen, Denmark
  • Odense University Hospital Odense, Denmark
View Trial Details
Active, Not Recruiting

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

NCT05290597

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • [email protected] Sydney, New South Wales, Australia
  • Westmead Hospital Sydney, New South Wales, Australia
  • Sydney Southwest Private Hospital Sydney, New South Wales, Australia
  • Cancer Care Wollongong Sydney, New South Wales, Australia
View Trial Details
Active, Not Recruiting

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

NCT04802356

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hospital Son Llatzer Palma de Mallorca, Balearic Islands, Spain
  • Hospital Universitario Marqués de Valdecilla Santander, Cantabria, Spain
  • Hospital Universitario de Salamanca Salamanca, Castille and León, Spain
  • Complejo Universitario Hospitalario de Santiago Santiago de Compostela, Galicia, Spain
View Trial Details

Related conditions